Talk on rapamycin, mTOR and aging in lab models, companion animals and humans
The description announces a talk by Dr. Matt Kaeberlein on how rapamycin and the mTOR pathway became central to aging research, including what is and is not known about healthy aging in people. [1]
Automatic summary · not editorially reviewed
The key findings
The description says rapamycin, found in soil bacteria from Easter Island and developed as an immunosuppressant, extended lifespan and improved healthspan measures in multiple laboratory species. [1]
The description says the talk will discuss discoveries that established mTOR inhibition as one of the most robust interventions for extending lifespan in laboratory models. [1]
The description says the talk will examine emerging evidence from companion animals and humans, including what is known and unknown about rapamycin's potential effects on healthy aging in people. [1]
The source at a glance
- Study type / format
- Video description of a lecture
- Population / context
- Laboratory species, companion animals and humans discussed in the announced talk
- Summary based on
- Creator description
- Original publication
- April 20, 2026
Rapamycin and mTOR in aging research
According to the description, aging is the greatest risk factor for most chronic diseases but has historically not been treated as a modifiable biological process. Discoveries in aging biology over the past two decades challenged that view. Rapamycin, originally found in soil bacteria from Easter Island and developed as an immunosuppressant, reportedly extended lifespan and improved healthspan measures in multiple laboratory species. These findings led to identifying the mTOR signaling pathway as a central regulator of aging biology.
Supporting source [1]
Announced scope: history, animals and humans
The description says the talk will give a historical overview of the scientific journey linking mTOR and rapamycin to aging biology. It will discuss key discoveries that established mTOR inhibition as one of the most robust interventions for extending lifespan in laboratory models. It will also examine emerging evidence from companion animals and humans, including what is known and what is still unknown about rapamycin's potential effects on healthy aging in people.
Supporting source [1]
Geroscience framing of age-related disease
Finally, the description states that Dr. Kaeberlein will place these findings in the broader context of geroscience and the growing effort to target the biology of aging as a strategy to delay or prevent multiple age-related diseases simultaneously. The description presents this as the planned framing of the lecture, not as a demonstrated outcome in people.
Supporting source [1]
How to interpret this
This is only the video description; the video and transcript were not reviewed. The described lifespan and healthspan findings concern laboratory species, and the human evidence is presented as emerging and partly unknown. The lecture framing is announced, not reported as completed.
Based on the creator’s description; the full video and transcript were not analyzed.
Source & supporting passages
UAZPharmacy · youtube.com · April 20, 2026